If you're exploring continuous glucose monitoring (CGM) options, you've likely heard about Eversense. This innovative CGM system offers a unique approach to managing diabetes by providing long-term, implantable glucose monitoring. If you're wondering about the company behind Eversense, this article provides a comprehensive overview of the manufacturer, its history, and what sets this device apart in the world of diabetes management.
Who Manufactures Eversense CGM?
The company responsible for developing and manufacturing the Eversense Continuous Glucose Monitoring (CGM) system is Sensogram Technologies, Inc. However, the Eversense brand and its development are primarily driven by Senseonics Holdings, Inc. Senseonics is a medical technology company focused on creating innovative solutions for diabetes management, with Eversense being its flagship product.
About Senseonics Holdings, Inc.
Senseonics Holdings, Inc. is a biotechnology company headquartered in Germantown, Maryland, United States. Founded in 1996, the company has dedicated itself to developing advanced glucose monitoring systems that improve the quality of life for people living with diabetes. Their core mission is to create innovative, minimally invasive, and long-lasting solutions that facilitate better glucose control.
Senseonics has garnered attention in the medical device industry for its focus on implantable CGM technology, which offers an alternative to traditional sensor-based systems that require frequent replacement. Their commitment to research and development has led to the creation of the Eversense CGM system, which is distinguished by its implantable sensor and long-term usage capabilities.
Development of the Eversense CGM System
The development of the Eversense CGM system was a collaborative effort involving extensive research, clinical trials, and technological innovation. The goal was to create a device that could provide consistent, accurate glucose readings over extended periods, reducing the hassle of frequent sensor replacements associated with traditional CGMs.
Unlike conventional CGMs that involve wearing a sensor on the skin surface for several days to weeks, Eversense features an implantable sensor that can stay in place for up to 90 days. The sensor communicates with a wearable transmitter that is worn externally, which then transmits glucose data to a smartphone app or compatible device.
Key Features of the Eversense System
- Long-term sensor lifespan: The sensor can remain implanted for up to 90 days, reducing the need for frequent replacements.
- Minimally invasive implantation and removal: The sensor is implanted and removed in a quick outpatient procedure performed by a healthcare professional.
- Vibration alerts: The Eversense system can alert users via gentle vibrations for high or low glucose levels, providing discreet notifications.
- Accurate readings: The system offers highly accurate glucose measurements, comparable to traditional fingerstick testing.
- Compatibility with smartphones: Data is transmitted wirelessly to a mobile app, allowing for easy monitoring and data sharing.
Manufacturing and Distribution
Senseonics oversees the manufacturing of the Eversense CGM system through its facilities, ensuring strict quality control and adherence to medical standards. The company collaborates with various healthcare providers and distributors to ensure the device's availability across different regions.
The distribution network includes partnerships with pharmacy chains, healthcare providers, and specialty clinics. This ensures that patients can access the device through their healthcare team, who can perform the implantation and removal procedures.
Regulatory Approvals and Global Reach
The Eversense CGM system has received regulatory approvals from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These approvals enable the device to be marketed and used by people with diabetes in the United States, Europe, and other regions.
Senseonics continues to seek approvals in additional countries to expand the availability of Eversense worldwide, aiming to reach more individuals who can benefit from its long-term glucose monitoring technology.
Innovation and Future Developments
Senseonics is committed to ongoing innovation in the diabetes management space. The company invests heavily in research and development to improve existing products and develop new solutions. Future developments may include:
- Enhanced sensor accuracy and longevity: Further extending the sensor lifespan or improving measurement precision.
- Integration with insulin delivery systems: Creating closed-loop systems that automatically adjust insulin doses based on real-time glucose data.
- Advanced data analytics: Offering more comprehensive insights into glucose patterns for better disease management.
- Smaller, more discreet devices: Developing less invasive, more comfortable implantable sensors.
Conclusion
In summary, the company behind the Eversense CGM system is Senseonics Holdings, Inc. This innovative firm has pioneered long-term, implantable glucose monitoring technology that offers significant advantages over traditional sensors. With a focus on improving the quality of life for people with diabetes, Senseonics continues to lead the way in medical device innovation, expanding access and refining its products for better health outcomes.
If you're interested in advanced diabetes management tools, understanding who makes Eversense helps you appreciate the technology and expertise behind this groundbreaking system. As the company advances its research and expands its global reach, the future of continuous glucose monitoring looks brighter than ever with Senseonics at the forefront.
Bizzfora
Bizzfora is a hub where business, entrepreneurship, and innovation take centre stage. Through practical insights on startups, leadership, strategy, marketing, finance, and business growth, our team explores the ideas and opportunities shaping today's entrepreneurial world.
0 comments